AZD1236, currently in Phase 2 trials, has shown an 80% preservation in nerve function following spinal cord injury.

VX-548 delivered significant improvements in pain with few adverse events.

Phase 3 trials for NVX-CoV2373 across 30,000 people found this vaccine candidate to be safe and effective for the prevention of COVID-19.

The FDA is working to expedite the delivery of diagnostic testing for COVID-19.

COVID-19 drug trials are underway, but the pandemic is disrupting clinical testing.

NKTR-181 is supposed to offer a lower frequency of opioid side effects. But are more opioids really the solution we need to the opioid crisis?

A new wave of drugs that suppress CGRP proteins to reduce migraines could be on the horizon.

Drugs to treat opioid dependence could be approved under new clinical endpoints other than reducing opioid use.

Apadaz oral tablets were approved for the short-term management of acute pain, at no more than 14 days of use.